Adagene announces updates to board of directors

Adagene (ADAG) announced updates to its board of directors, including the following: Mervyn Turner, Ph.D., is appointed as a director. Dr. Turner accumulated over 25 years of experience at Merck Research Laboratories (MRK) in pharmaceuticals drug discovery, research and development, licensing and business development, emerging markets analysis, and strategy development and implementation. Fangyong Du, Ph.D., is appointed as a director. Dr. Du joined Adagene as Vice President of Technology Development in January 2012 and has served as Chief Technology Officer since May 2019. Yumeng Wang, replaces Lefei Sun as a director immediately prior to filing of the annual report of the Company for the year of 2022, as designated by General Atlantic Singapore AI Pte. pursuant to Adagene’s current effective memorandum and articles of association. Wang is a vice president at General Atlantic, primarily responsible for investments in healthcare and life sciences sectors. As a result of Yumeng Wang’s replacement of Lefei Sun, he has resigned from the Board. Additionally, Yuwen Liu has resigned from the Board and audit committee of the Board effective upon filing of the Annual Report, due to expiration of her initial appointment as a director and an audit committee member. Each of Lefei Sun and Yuwen Liu has confirmed that there is no disagreement with the Board and there is no matter relating to his or her resignation that needs to be brought to the attention of the shareholders of the Company.